Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

INSM – Insmed Incorporated

Insmed Incorporated
INSM
$73.66
Name : Insmed Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,416,359,936.00
EPSttm : -5.93
finviz dynamic chart for INSM
Insmed Incorporated
$73.66
1.26%
$0.92

Float Short %

9.25

Margin Of Safety %

Put/Call OI Ratio

1.14

EPS Next Q Diff

0.05

EPS Last/This Y

0.41

EPS This/Next Y

1.6

Price

72.74

Target Price

97

Analyst Recom

1.05

Performance Q

-3.04

Relative Volume

1.23

Beta

0.79

Ticker: INSM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07INSM68.350.970.2168974
2025-05-08INSM65.630.950.5570058
2025-05-09INSM65.080.950.8272341
2025-05-12INSM67.780.945.0274432
2025-05-13INSM65.690.942.5374338
2025-05-14INSM65.611.021.9179898
2025-05-15INSM67.171.0121.9481464
2025-05-16INSM68.150.990.5780909
2025-05-19INSM67.861.070.5668676
2025-05-20INSM68.491.070.2069082
2025-05-21INSM66.031.067.2769660
2025-05-22INSM66.171.110.5171472
2025-05-23INSM67.531.072.2874402
2025-05-27INSM68.051.080.3574999
2025-05-28INSM66.371.091.5175353
2025-05-29INSM69.21.090.5175558
2025-05-30INSM69.711.090.7376773
2025-06-02INSM71.71.094.1578184
2025-06-03INSM73.081.116.6979723
2025-06-04INSM73.691.210.5483249
2025-06-05INSM72.741.141.4787562
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07INSM68.28-28.4-83.0-5.32
2025-05-08INSM65.68-28.4-42.0-5.32
2025-05-09INSM65.0830.4-70.0-4.66
2025-05-12INSM67.7530.4-115.5-4.66
2025-05-13INSM65.7131.1-7.4-5.05
2025-05-14INSM65.6133.1-35.2-5.05
2025-05-15INSM67.1533.1-9.5-5.05
2025-05-16INSM68.1633.1-0.8-5.05
2025-05-19INSM67.8832.915.3-5.11
2025-05-20INSM68.5132.33.6-5.16
2025-05-21INSM66.0132.345.7-5.16
2025-05-22INSM66.2032.39.6-5.16
2025-05-23INSM67.5132.3-6.7-5.16
2025-05-27INSM68.0232.35.5-5.16
2025-05-28INSM66.3732.334.4-5.16
2025-05-29INSM69.2032.3-27.3-5.16
2025-05-30INSM69.7332.35.2-5.16
2025-06-02INSM71.6832.3-13.6-5.16
2025-06-03INSM73.0832.3-5.9-5.16
2025-06-04INSM73.7032.34.3-5.16
2025-06-05INSM72.7432.324.0-5.16
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07INSM-16.722.308.49
2025-05-08INSM-16.722.308.49
2025-05-09INSM-16.722.308.49
2025-05-12INSM-16.721.258.85
2025-05-13INSM-16.721.258.85
2025-05-14INSM-16.701.258.85
2025-05-15INSM-14.221.258.90
2025-05-16INSM-14.221.258.90
2025-05-19INSM-17.902.658.86
2025-05-20INSM-17.092.658.86
2025-05-21INSM-17.092.658.86
2025-05-22INSM-17.092.658.86
2025-05-23INSM-17.522.658.86
2025-05-27INSM-16.953.798.87
2025-05-28INSM-17.013.799.25
2025-05-29INSM-17.013.799.25
2025-05-30INSM-17.013.799.25
2025-06-02INSM-17.014.509.25
2025-06-03INSM-17.444.509.25
2025-06-04INSM-17.444.509.25
2025-06-05INSM-17.884.509.25
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.42

Avg. EPS Est. Current Quarter

-1.31

Avg. EPS Est. Next Quarter

-1.37

Insider Transactions

-17.88

Institutional Transactions

4.5

Beta

0.79

Average Sales Estimate Current Quarter

103

Average Sales Estimate Next Quarter

113

Fair Value

Quality Score

30

Growth Score

53

Sentiment Score

75

Actual DrawDown %

14.3

Max Drawdown 5-Year %

-63.3

Target Price

97

P/E

Forward P/E

PEG

P/S

34.77

P/B

133.44

P/Free Cash Flow

EPS

-5.95

Average EPS Est. Cur. Y​

-5.16

EPS Next Y. (Est.)

-3.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-265.93

Relative Volume

1.23

Return on Equity vs Sector %

-1045.9

Return on Equity vs Industry %

-1028

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.15

EBIT Estimation

24
Insmed Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 1271
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading